Latest Regulatory Approval News

Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.

NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.

Lanthanein Resources has completed initial drilling phases at its Lady Grey Project and secured a six-month extension on its farm-in agreement, positioning the company for a critical assessment of its gold exploration prospects.

Patronus Resources reports significant drilling progress across its Western Australia and Northern Territory projects, with strong assay results at Mertondale and a robust cash position supporting ongoing exploration.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

NGX Limited reports significant progress in its uranium exploration in Namibia and graphite development in Malawi, alongside strategic leadership changes and a strong financial position.

Arafura Rare Earths has secured a pivotal A$200 million investment commitment from the National Reconstruction Fund Corporation, advancing its Nolans Project towards a final investment decision targeted for mid-2025.

Moab Minerals reports significant progress in its uranium exploration portfolio, including pending drill results at Manyoni, acquisition of strategic tenements in Tanzania, and permitting for a follow-up drill program at the REX project in Colorado.

Torque Metals and Aston Minerals have updated shareholders on their merger, confirming the share exchange ratio and appointing an independent expert to assess the deal's fairness.

Tissue Repair Limited has commenced patient randomisation in its Phase 3 trial of TR987®, targeting chronic venous leg ulcers, aiming to confirm promising earlier results and potentially transform wound healing treatment.